US HB8662 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on October 23 2020 - 25% progression, died in committee
Action: 2020-10-23 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 23 2020 - 25% progression, died in committee
Action: 2020-10-23 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases. HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.
Title
Accelerating Access to Critical Therapies for ALS Act
Sponsors
History
Date | Chamber | Action |
---|---|---|
2020-10-23 | House | Referred to the House Committee on Energy and Commerce. |
2020-10-23 | House | Introduced in House |
Same As/Similar To
SB4867 (Same As) 2020-10-26 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Advisory bodies
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Government information and archives
Health
Health care coverage and access
Health care quality
Health information and medical records
Health programs administration and funding
Health promotion and preventive care
Medical research
Medical tests and diagnostic methods
Neurological disorders
Public contracts and procurement
Research administration and funding
Research and development
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Government information and archives
Health
Health care coverage and access
Health care quality
Health information and medical records
Health programs administration and funding
Health promotion and preventive care
Medical research
Medical tests and diagnostic methods
Neurological disorders
Public contracts and procurement
Research administration and funding
Research and development
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/8662/all-info |
Text | https://www.congress.gov/116/bills/hr8662/BILLS-116hr8662ih.pdf |